Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 1/20 | 0.72 |
| ▸ | ROR1 | Q01973 | 8/20 | 0.64 |
| ▸ | ABL1 | P00519 | 11/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12652639 | 1.00 | CSF1R (0.72) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL589881 | 0.88 | CSF1R (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL15096062 | 0.88 | ROR1 (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL29506341 | 0.88 | CSF1R (0.67) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22243490 | 0.87 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL29493472 | 0.87 | CSF1R (0.66) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL15088585 | 0.84 | CSF1R (0.62) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL23790315 | 0.84 | CSF1R (0.52) | CSF1RROR1ABL1 | |
| SCHEMBL19317721 | 0.84 | ROR1 (0.79) | CSF1RROR1ABL1CYP3A4KCNH2 | |
| SCHEMBL22580709 | 0.84 | CSF1R (0.61) | CSF1RROR1ABL1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119462376-A | Synthesis process of panatinib key intermediate | 湖北广济医药科技有限公司 | 2025-02-18 | — | — | CN | disclosed |
| EP-4326269-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | Oregon Health & Science University (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022225972-A1 | COMPOUNDS WITH IMPROVED CARDIAC SAFETY FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2022-10-27 | — | — | WO | disclosed |